Introduction: Resistance to thyroid hormone β (RTHβ) is an inherited syndrome caused by dominant negative variants in the THRB gene (NM_000461.5). The clinical picture of RTHβ is variable, and patients harboring the same variant may display different degrees of disease severity. Case Presentation: A 30-year-old man presented with thyrotoxicosis and central hyperthyroidism and was found to have a novel variant in the exon 10 of THRB gene (c.C1282G, p.L428V), located within the third hot spot region of the C-terminal of the receptor. Surprisingly, the same variant was found in two other relatives with an apparent normal thyroid function at initial screening. After exclusion of a TSH-secreting adenoma and serum interference in the proband, and the finding that exogenous levothyroxine failed to suppress the TSH in the brother affected by nodular goiter, relatives’ thyroid function tests (TFTs) were reassessed with additional analytical method revealing biochemical features consistent with RTHβ in all carriers of the p.L428V variant. Functional studies showed a slightly impaired in vitro transcriptional activity of p.L428V. Interestingly‚ the expression of the human p.L428V thyroid hormone receptor beta in the zebrafish embryo background generated a phenotype consistent with RTHβ. Conclusion: Variable results of TFTs on some immunoassays can be a cause of RTHβ diagnostic delay, but the genotype-phenotype correlation in this family and functional studies support p.L428V as a novel THRB variant expanding the spectrum of gene variants causing RTHβ. In vivo, rather than in vitro, functional assays may be required to demonstrate the dominant negative action of THRB variants.

1.
Refetoff
S
,
Bassett
JH
,
Beck-Peccoz
P
,
Bernal
J
,
Brent
G
,
Chatterjee
K
,
Classification and proposed nomenclature for inherited defects of thyroid hormone action, cell transport, and metabolism
.
Thyroid
.
2014 Mar
;
24
(
3
):
407
9
. .
2.
Achermann
JC
,
Schwabe
J
,
Fairall
L
,
Chatterjee
K
.
Genetic disorders of nuclear receptors
.
J Clin Invest
.
2017 Apr
;
127
(
4
):
1181
92
. .
3.
Persani
L
,
Campi
I
.
Syndromes of Resistance to Thyroid Hormone Action
.
Exp Suppl
.
2019
;
111
:
55
84
.
4.
Collingwood
TN
,
Wagner
R
,
Matthews
CH
,
Clifton-Bligh
RJ
,
Gurnell
M
,
Rajanayagam
O
,
A role for helix 3 of the TRbeta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone
.
EMBO J
.
1998 Aug
;
17
(
16
):
4760
70
. .
5.
Richards
S
,
Aziz
N
,
Bale
S
,
Bick
D
,
Das
S
,
Gastier-Foster
J
,
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology
.
Genet Med
.
2015 May
;
17
(
5
):
405
24
. .
6.
Collingwood
TN
,
Adams
M
,
Tone
Y
,
Chatterjee
VK
.
Spectrum of transcriptional, dimerization, and dominant negative properties of twenty different mutant thyroid hormone beta-receptors in thyroid hormone resistance syndrome
.
Mol Endocrinol
.
1994 Sep
;
8
(
9
):
1262
77
. .
7.
Nagaya
T
,
Jameson
JL
.
Distinct dimerization domains provide antagonist pathways for thyroid hormone receptor action
.
J Biol Chem
.
1993 Nov 15
;
268
(
32
):
24278
82
. .
8.
Hayashi
Y
,
Sunthornthepvarakul
T
,
Refetoff
S
.
Mutations of CpG dinucleotides located in the triiodothyronine (T3)-binding domain of the thyroid hormone receptor (TR) beta gene that appears to be devoid of natural mutations may not be detected because they are unlikely to produce the clinical phenotype of resistance to thyroid hormone
.
J Clin Invest
.
1994
;
94
:
607
15
. .
9.
Campi
I
,
Covelli
D
,
Moran
C
,
Fugazzola
L
,
Cacciatore
C
,
Orlandi
F
,
The differential diagnosis of discrepant thyroid function tests: insistent pitfalls and updated flow-chart based on a long-standing experience
.
Front Endocrinol
.
2020 Jul
;
11
:
432
. .
10.
Trimarchi
F
,
Benvenga
S
,
Costante
G
,
Barbera
C
,
Melluso
R
,
Marcocci
C
,
Identification and characterization of circulating thyroid hormone autoantibodies in thyroid diseases, in autoimmune non thyroid illnesses and in lymphoreticular system disorders
.
J Endocrinol Invest
.
1983 Jun
;
6
(
3
):
203
9
. .
11.
Beato-Víbora
PI
,
Alejo-González
S
.
Avoiding misdiagnosis due to antibody interference with serum free thyroxin
.
Int J Endocrinol Metab
.
2016 Nov
;
15
(
1
):
e37792
. .
12.
Marelli
F
,
Carra
S
,
Rurale
G
,
Cotelli
F
,
Persani
L
.
In vivo functional consequences of human THRA variants expressed in the zebrafish
.
Thyroid
.
2017
;
27
(
2
):
279
91
. .
13.
Dieu
X
,
Sueur
G
,
Moal
V
,
Boux de Casson
F
,
Bouzamondo
N
,
Bouhours
N
,
Apparent resistance to thyroid hormones: from biological interference to genetics
.
Ann Endocrinol
.
2019 Nov
;
80
(
5-6
):
280
5
. .
14.
Pappa
T
,
Refetoff
S
.
Resistance to thyroid hormone beta: a focused review
.
Front Endocrinol
.
2021 Mar 31
;
12
:
656551
. .
15.
Korwutthikulrangsri
M
,
Dosiou
C
,
Dumitrescu
AM
,
Refetoff
S
.
A novel G385E variant in the cold region of the T3-binding domain of thyroid hormone receptor beta gene and investigations to assess its clinical significance
.
Eur Thyroid J
.
2019 Dec
;
8
(
6
):
293
7
. .
16.
Araque
KA
,
Klubo-Gwiezdzinska
J
,
Nieman
LK
,
Welsh
K
,
Soldin
SJ
.
Assessment of thyroid function tests and harmonization: opinion on thyroid hormone harmonization
.
Ther Adv Endocrinol Metab
.
2019 Dec
;
10
:
2042018819897049
. .
17.
Giovannini
S
,
Zucchelli
GC
,
Iervasi
G
,
Iervasi
A
,
Chiesa
MR
,
Mercuri
A
,
Multicentre comparison of free thyroid hormones immunoassays: the Immunocheck study
.
Clin Chem Lab Med
.
2011 Oct
;
49
(
10
):
1669
76
. .
18.
Steele
BW
,
Wang
E
,
Klee
GG
,
Thienpont
LM
,
Soldin
SJ
,
Sokoll
LJ
,
Analytic bias of thyroid function tests: analysis of a college of American pathologists fresh frozen serum pool by 3900 clinical laboratories
.
Arch Pathol Lab Med
.
2005
;
129
(
3
):
310
7
.
19.
Parker
ML
,
Adeli
K
;
CSCC Working Group on Reference Interval Harmonization
.
Pediatric and adult reference interval harmonization in Canada: an update
.
Clin Chem Lab Med
.
2018 Dec 19
;
57
(
1
):
57
60
.
20.
Després
N
,
Grant
AM
.
Antibody interference in thyroid assays: a potential for clinical misinformation
.
Clin Chem
.
1998 Mar
;
44
(
3
):
440
54
.
21.
Schoenmakers
N
,
Moran
C
,
Campi
I
,
Agostini
M
,
Bacon
O
,
Rajanayagam
O
,
A novel albumin gene mutation (R222I) in familial dysalbuminemic hyperthyroxinemia
.
J Clin Endocrinol Metab
.
2014 Jul
;
99
(
7
):
E1381
6
. .
22.
Koulouri
O
,
Moran
C
,
Halsall
D
,
Chatterjee
K
,
Gurnell
M
.
Pitfalls in the measurement and interpretation of thyroid function tests
.
Best Pract Res Clin Endocrinol Metab
.
2013 Dec
;
27
(
6
):
745
62
. .
23.
Dieu
X
,
Bouzamondo
N
,
Briet
C
,
Illouz
F
,
Moal
V
,
Boux de Casson
F
,
Familial dysalbuminemic hyperthyroxinemia: an underdiagnosed entity
.
J Clin Med
.
2020 Jul 3
;
9
(
7
):
2105
. .
24.
Fujisawa
H
,
Gagné
J
,
Dumitrescu
AM
,
Refetoff
S
.
Very severe resistance to thyroid hormone β in one of three affected members of a family with a novel mutation in the THRB gene
.
Thyroid
.
2019 Oct
;
29
(
10
):
1518
20
. .
25.
Medici
M
,
Visser
WE
,
Visser
TJ
,
Peeters
RP
.
Genetic determination of the hypothalamic-pituitary-thyroid axis: where do we stand?
Endocr Rev
.
2015 Apr
;
36
(
2
):
214
44
. .
26.
Hayashi
Y
,
Weiss
RE
,
Sarne
DH
,
Yen
PM
,
Sunthornthepvarakul
T
,
Marcocci
C
,
Do clinical manifestations of resistance to thyroid hormone correlate with the functional alteration of the corresponding mutant thyroid hormone-beta receptors?
J Clin Endocrinol Metab
.
1995 Nov
;
80
(
11
):
3246
56
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.